IFI30 and neoplasm: Targeting IFI30 could confer several advantages, including inhibiting tumor progression by inducing cell apoptosis and senescence, enhancing chemotherapy sensitivity (such as promoting DDP‐induced apoptosis), and remodeling the tumor microenvironment (such as reprogramming the SASP).